Hikal informs about submission of unaudited financial results

04 Feb 2025 Evaluate
Hikal has informed that, the Board of Directors of the Company at its meeting held today i.e., February 4, 2025, have considered and approved the unaudited financial results (Standalone and Consolidated) of the Company for the quarter and the period ended December 31, 2024. In terms of Regulation 33 of SEBI (LODR) Regulations, 2015, the unaudited financial results (Standalone and Consolidated) for the quarter and the period ended December 31, 2024 along with the Limited Review report from the Statutory Auditors are enclosed; Declared an Interim Dividend on the Equity Shares of the Company for the financial year 2024-25 @ 30% [Re 0.60 per equity share, nominal value of Rs 2 each]. The Company has fixed Record Date as Saturday, February 08, 2025, to ascertain the shareholders of the Company entitled for the payment of Interim Dividend. The Interim Dividend will be paid to the shareholder on or before Wednesday, March 5, 2025. The trading window, for trading in securities of the Company by Designated Persons, which remained closed with effect from January 1, 2025, will re-open on February 7, 2025. The special closure of trading window intimated by the Company vide its letter dated May 31, 2023 read with the outcome of Board Meeting dated November 12, 2024, will continue to remain closed for Directors, KMPs and specified senior management personnel until informed otherwise. The Meeting commenced at 11.45 am and concluded at 02.30 pm. 

The above information is a part of company’s filings submitted to BSE.

Hikal Share Price

400.10 -4.65 (-1.15%)
28-Mar-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1735.45
Dr. Reddys Lab 1144.05
Cipla 1441.70
Lupin 2026.50
Zydus Lifesciences 885.70
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
Please wait your portfolio is updating...